Compare Fresenius Kabi Onco. with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DR. REDDYS LAB - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DR. REDDYS LAB FRESENIUS KABI ONCO./
DR. REDDYS LAB
 
P/E (TTM) x 22.1 16.9 130.7% View Chart
P/BV x 3.1 3.2 96.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   DR. REDDYS LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DR. REDDYS LAB
Mar-19
FRESENIUS KABI ONCO./
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1762,875 6.1%   
Low Rs791,888 4.2%   
Sales per share (Unadj.) Rs37.7930.2 4.1%  
Earnings per share (Unadj.) Rs5.1117.4 4.3%  
Cash flow per share (Unadj.) Rs6.7185.8 3.6%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5844.4 5.0%  
Shares outstanding (eoy) m158.23166.07 95.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.6 131.9%   
Avg P/E ratio x25.020.3 123.2%  
P/CF ratio (eoy) x18.912.8 147.6%  
Price / Book Value ratio x3.02.8 106.1%  
Dividend payout %017.0 0.0%   
Avg Mkt Cap Rs m20,135395,496 5.1%   
No. of employees `0001.222.0 5.2%   
Total wages/salary Rs m70333,562 2.1%   
Avg. sales/employee Rs Th5,176.27,032.8 73.6%   
Avg. wages/employee Rs Th610.41,527.9 40.0%   
Avg. net profit/employee Rs Th699.6887.7 78.8%   
INCOME DATA
Net Sales Rs m5,963154,482 3.9%  
Other income Rs m183,375 0.5%   
Total revenues Rs m5,981157,857 3.8%   
Gross profit Rs m1,43031,782 4.5%  
Depreciation Rs m25811,348 2.3%   
Interest Rs m-26889 -2.9%   
Profit before tax Rs m1,21622,920 5.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3423,858 8.9%   
Profit after tax Rs m80619,500 4.1%  
Gross profit margin %24.020.6 116.6%  
Effective tax rate %28.116.8 167.2%   
Net profit margin %13.512.6 107.1%  
BALANCE SHEET DATA
Current assets Rs m5,102111,101 4.6%   
Current liabilities Rs m2,38558,973 4.0%   
Net working cap to sales %45.633.7 135.0%  
Current ratio x2.11.9 113.5%  
Inventory Days Days15079 189.1%  
Debtors Days Days11394 120.3%  
Net fixed assets Rs m5,148101,245 5.1%   
Share capital Rs m158830 19.1%   
"Free" reserves Rs m6,556139,406 4.7%   
Net worth Rs m6,732140,236 4.8%   
Long term debt Rs m95222,000 4.3%   
Total assets Rs m10,388224,656 4.6%  
Interest coverage x-45.826.8 -170.9%   
Debt to equity ratio x0.10.2 90.2%  
Sales to assets ratio x0.60.7 83.5%   
Return on assets %7.59.1 82.7%  
Return on equity %12.013.9 86.1%  
Return on capital %14.614.9 97.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29888,673 6.0%   
Fx outflow Rs m1,77219,104 9.3%   
Net fx Rs m3,52569,569 5.1%   
CASH FLOW
From Operations Rs m1,27428,704 4.4%  
From Investments Rs m-1,204-7,727 15.6%  
From Financial Activity Rs m-196-21,326 0.9%  
Net Cashflow Rs m-126-314 40.2%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 9.6 35.3 27.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   42,599 75,885 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   FDC LTD.  UNICHEM LAB  WYETH LTD  ELDER PHARMA  ALEMBIC LTD  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS